Please ensure Javascript is enabled for purposes of website accessibility
OnCore Login

Return to Trial Database

HCRN-AML24-687

Pilot Single Arm Phase 2 study of Olutasidenib in Relapsed IDH1 Mutated AML Patients Who Have Previously Received Venetoclax

Status

Currently Enrolling

Cancer Type(s)

Leukemia

Study Contact

(317) 921-2050
studies@hoosiercancer.org

Trial Locations

All sites in which the trial HCRN-AML24-687 being conducted in.
Wake Forest Baptist Medical Center Comprehensive Cancer Center